Karin Flynn-Rodden, MD
Allergy & Immunology · Philadelphia, PANPI 1467494096
Payments from drug & device makers
Across 621 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Sanofi$1K
- CSL Behring$847
- Genentech USA, Inc.$761
- plus $3K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 145 | $3,275 |
| AstraZeneca | 128 | $2,987 |
| Regeneron Healthcare Solutions, Inc. | 79 | $1,730 |
| Sanofi | 41 | $1,474 |
| CSL Behring | 33 | $847 |
| Genentech USA, Inc. | 34 | $761 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $491 |
| Novartis | 23 | $479 |
| Biocryst US Sales Co., LLC | 21 | $426 |
| Boehringer Ingelheim | 17 | $348 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $261 |
| Kaleo, Inc. | 12 | $211 |
| Optinose US, Inc. | 7 | $205 |
| Pfizer | 9 | $146 |
| Grifols USA, LLC | 4 | $111 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Incyte Corporation | 5 | $95 |
| Teva Pharmaceuticals USA, Inc. | 4 | $70 |
| Hikma Pharmaceuticals USA | 4 | $68 |
| Aimmune Therapeutics, Inc. | 4 | $64 |
| Mylan Specialty L.p. | 2 | $45 |
| Merck | 3 | $44 |
| Aytu Biopharma, Inc. | 2 | $35 |
| Amgen(2 entities) | 2 | $35 |
| Circassia Inc. | 2 | $32 |
| Shire North American Group Inc | 2 | $31 |
| Bio Products Laboratory USA, Inc. | 2 | $31 |
| Blueprint Medicines Corporation | 1 | $30 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Greer Laboratories, Inc. | 1 | $21 |
| AbbVie | 1 | $19 |
| Philips North America LLC | 1 | $18 |
How this compares
$14,512 in reported general payments places this provider in the 80th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Philadelphia
- Drew WeissmanPhiladelphia$15.3M
- Rahul DattaPhiladelphia$198K
- Arnold LevinsonPhiladelphia$95K
- John BossoPhiladelphia$86K
- Elias AklPhiladelphia$80K
- Neha SirohiPhiladelphia$62K
- Marc GoldsteinPhiladelphia$22K
- Raquel EmpedradPhiladelphia$21K
- Donald DvorinPhiladelphia$10K
- Irene HaralabatosPhiladelphia$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.